Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Rating of “Moderate Buy” by Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $40.8182.

A number of brokerages have weighed in on CAPR. Maxim Group boosted their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Roth Mkm boosted their price objective on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Oppenheimer upped their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Industrial Alliance Securities set a $48.00 target price on Capricor Therapeutics in a research note on Wednesday, December 3rd. Finally, UBS Group set a $50.00 price target on Capricor Therapeutics in a research note on Monday, December 15th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC bought a new stake in shares of Capricor Therapeutics during the third quarter worth approximately $28,000. Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $36,000. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the last quarter. GoalVest Advisory LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth $59,000. Finally, Tower Research Capital LLC TRC grew its holdings in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $22.61 on Friday. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The stock has a market capitalization of $1.03 billion, a PE ratio of -12.56 and a beta of 0.22. The stock’s fifty day moving average is $22.98 and its 200-day moving average is $12.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). As a group, analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.